- Home
- BESS vs CRVO Comparison
BESS vs CRVO Comparison
Compare BESS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BESS | CRVO |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 25.9M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BESS | CRVO |
|---|---|---|
| Price | $1.86 | $3.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.75 | ★ $15.40 |
| AVG Volume (30 Days) | 50.2K | ★ 172.4K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $168,880.00 | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $206.88 | $525.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.00 | $2.13 |
| 52 Week High | $6.45 | $10.00 |
Technical Indicators
Market Signals| Indicator | BESS | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 74.49 |
| Support Level | N/A | $2.44 |
| Resistance Level | $3.17 | $3.86 |
| Average True Range (ATR) | 0.28 | 0.15 |
| MACD | -0.07 | 0.09 |
| Stochastic Oscillator | 6.85 | 92.63 |
Price Performance
Historical ComparisonAbout BESS Bimergen Energy Corporation Common Stock
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.